Table 2 Characteristics of the sample according to mortality at 60 days - Univariate analysis
Variable | Alive (N= 265) | Dead (N= 154) | p value |
|---|---|---|---|
Median Age (Q1; Q3) | 88 (84;92) | 90 (85;93.3) | 0.043 |
Gender. % Female | 72.5 | 70.1 | 0.611 |
Type of nursing home. % private | 68.3 | 68.2 | 0.980 |
Geriatric Assessment. % | |||
Barthel <60 | 57.3 | 75 | < 0.001 |
FAC <3 | 46.8 | 69.4 | < 0.001 |
GDS 6-7 | 39.9 | 50.7 | 0.026 |
Malnutrition | 59.8 | 72.2 | 0.026 |
Median Charlson (Q1; Q3) | 2 (1;3) | 2 (1;3.3) | 0.129 |
Median symptom evolution time (days) (Q1; Q3) | 3 (1;7) | 3 (1;6.8) | 0.486 |
Symptoms. % | |||
Cough | 32.1 | 26.6 | 0.241 |
Respiratory failure (SatO2 ≤ 92%) | 64.5 | 79.9 | < 0.001 |
Tachypnea (FR ≥ 30 rpm) | 12.1 | 30.5 | < 0.001 |
Dyspnea | 12.1 | 23.4 | 0.002 |
Fever (Tª ≥ 38ºC) | 36.2 | 57.4 | < 0.001 |
Delirium | 16.2 | 25.3 | 0.024 |
Functional impairment | 20.4 | 19.5 | 0.825 |
Falls | 4.5 | 2.6 | 0.32 |
Eating Disorder | 15.5 | 24 | 0.030 |
Referral to emergency department % | 29.1 | 34.3 | 0.253 |
Treatment % | |||
Hydroxychloroquine | 64.9 | 63 | 0.693 |
Lopinavir/Ritonavir | 4.9 | 5.2 | 0.896 |
Azithromycin | 54.3 | 51.3 | 0.548 |
Ceftriaxone | 22.6 | 40.9 | < 0.001 |
Amoxicillin-Clavulanic Acid | 25.7 | 25.3 | 0.939 |
Other Antibiotics | 27.2 | 30.5 | 0.464 |
Corticosteroids | 23.4 | 32.5 | 0.043 |
HBPM | 24.9 | 22.7 | 0.615 |